These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16454836)

  • 1. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Am J Gastroenterol; 2006 Feb; 101(2):311-7. PubMed ID: 16454836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L; Curtis SP; Langman M; Jensen DM; Cryer B; Kaur A; Cannon CP
    Gastroenterology; 2008 Nov; 135(5):1517-25. PubMed ID: 18823986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
    van der Heijde D; Baraf HS; Ramos-Remus C; Calin A; Weaver AL; Schiff M; James M; Markind JE; Reicin AS; Melian A; Dougados M
    Arthritis Rheum; 2005 Apr; 52(4):1205-15. PubMed ID: 15818702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP; Curtis SP; Bolognese JA; Laine L;
    Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
    J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
    Mahadevan U; Loftus EV; Tremaine WJ; Sandborn WJ
    Am J Gastroenterol; 2002 Apr; 97(4):910-4. PubMed ID: 12008668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
    Gossec L; van der Heijde D; Melian A; Krupa DA; James MK; Cavanaugh PF; Reicin AS; Dougados M
    Ann Rheum Dis; 2005 Nov; 64(11):1563-7. PubMed ID: 15731291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].
    Curtis SP; Bockow B; Fisher C; Olaleye J; Compton A; Ko AT; Reicin AS
    BMC Musculoskelet Disord; 2005 Dec; 6():58. PubMed ID: 16321158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of etoricoxib in patients with reactions to NSAIDs.
    Quercia O; Emiliani F; Foschi FG; Stefanini GF
    J Investig Allergol Clin Immunol; 2008; 18(3):163-7. PubMed ID: 18564626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico.
    Ramos-Remus CR; Hunsche E; Mavros P; Querol J; Suarez R
    Curr Med Res Opin; 2004 May; 20(5):691-8. PubMed ID: 15140335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoricoxib for pain management during thyroid surgery--a prospective, placebo-controlled study.
    Smirnov G; Terävä M; Tuomilehto H; Hujala K; Seppänen M; Kokki H
    Otolaryngol Head Neck Surg; 2008 Jan; 138(1):92-7. PubMed ID: 18165000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.
    Bingham CO; Smugar SS; Wang H; Peloso PM; Gammaitoni A
    Pain Med; 2011 Mar; 12(3):352-61. PubMed ID: 21332932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
    Gottesdiener K; Schnitzer T; Fisher C; Bockow B; Markenson J; Ko A; DeTora L; Curtis S; Geissler L; Gertz BJ;
    Rheumatology (Oxford); 2002 Sep; 41(9):1052-61. PubMed ID: 12209041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoricoxib.
    Cochrane DJ; Jarvis B; Keating GM
    Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
    Bickham K; Kivitz AJ; Mehta A; Frontera N; Shah S; Stryszak P; Popmihajlov Z; Peloso PM
    BMC Musculoskelet Disord; 2016 Aug; 17():331. PubMed ID: 27502582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
    Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
    Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.